HIV Treatment: A 40-Year Revolution
In 1987, zidovudine (AZT) became the first antiretroviral medicine approved for HIV — offering modest benefit at significant toxicity. By the mid-1990s, AIDS was the leading cause of death in Americans ages 25-44. Today, a person diagnosed with HIV at age 20 and started on effective treatment can expect to live into their 70s — a near-normal lifespan.
This transformation is the result of one of the most remarkable pharmacological achievements in history: the development of combination antiretroviral therapy (ART) that can suppress HIV replication to undetectable levels.
How HIV Replicates (and How Medicines Stop It)
HIV must complete a replication cycle to spread through the body:
1. Attachment/Entry — HIV binds CD4 receptor and CCR5/CXCR4 co-receptors on T cells 2. Fusion — viral envelope fuses with cell membrane 3. Reverse transcription — viral RNA converted to DNA by reverse transcriptase 4. Integration — viral DNA integrated into host genome by integrase 5. Transcription/translation — viral proteins produced 6. Assembly/Budding — new viral particles assembled 7. Maturation — protease cleaves polyproteins; infectious virions released
Each step is a potential medicine target.
Antiretroviral Medicine Classes
#
NRTIs (Nucleoside/Nucleotide Reverse Transcriptase Inhibitors)
#
NNRTIs (Non-Nucleoside Reverse Transcriptase Inhibitors)
#
Integrase Strand Transfer Inhibitors (INSTIs)
#
Protease Inhibitors (PIs)
#
Entry/Fusion Inhibitors
Preferred First-Line Regimens (2024)
DHHS guidelines recommend these preferred regimens:
Undetectable = Untransmittable (U=U)
Perhaps the most important public health advance in HIV: people with HIV who achieve and maintain an undetectable viral load (< 200 copies/mL) cannot sexually transmit HIV to their partners. This was definitively proven by the PARTNER and PARTNER 2 studies — over 100,000 condomless sex acts with zero transmissions.
U=U has profound implications for the stigma of HIV and for adherence motivation.
Pre-Exposure Prophylaxis (PrEP)
PrEP allows HIV-negative individuals at high risk to prevent infection:
PrEP requires HIV testing before starting, every 3 months while on PrEP, and kidney function monitoring with TDF.
Frequently Asked Questions
How quickly does HIV treatment work?
Viral load typically drops by 90% within 2 weeks of starting ART and reaches undetectable levels (< 200 copies/mL) within 3-6 months. CD4 count recovers more slowly — often 50-100 cells/mm³ per year. The goal is viral suppression sustained indefinitely.
What happens if I miss doses of HIV medication?
Missed doses allow viral replication, increasing viral load and the risk of developing medicine resistance mutations. With high-barrier regimens (dolutegravir, bictegravir), occasional missed doses are less likely to cause resistance than with older medicines. Consistent adherence is still critical — aim for >95%.
Can HIV ever be cured?
As of 2024, there have been about 7 confirmed functional cures via bone marrow transplantation in patients who also had leukemia. For the general HIV population, a cure remains elusive due to HIV's latent reservoir in long-lived memory T cells. Research into long-acting medications, gene therapy, and latency-reversing agents is ongoing.
Can someone with HIV have children?
Yes. With effective ART, HIV-positive individuals can have children without transmitting HIV to their partners or babies. With appropriate management (ART for the parent, PrEP for HIV-negative partners, and antiretroviral prophylaxis for the newborn), mother-to-child transmission risk is reduced to under 1%.
Medicines Mentioned in This Article
Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult your healthcare provider before making any medication decisions.